Retour

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Stocks Earnings Releases and Operating Results

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

GlobeNewswire Inc. • 09/05/2024 à 13:30:00
Eledon Pharmaceuticals, Inc. Common Stock
Address: 19800 MACARTHUR BLVD.
Postal Code: 92612
City: IRVINE
State: CA
Phone Number: 949-238-8090
Website: https://www.eledon.com
Status: Active
Company Info

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

List Date2014-09-17
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001404281
Composite figiBBG00241S542
Share Class figiBBG00241S579
Market Cap114,529,314 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees20
Share Class Shares Outstanding38510000
Weighted Shares Outstanding37923614
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
3.19
2.775
2.47
2.275
2.23
Variance
14.95%
12.67%
5.56%
2.02%
-3.04%
Open
2.775
2.463
2.34
2.23
2.3
Highest
3.269
2.935
2.515
2.54
2.3
Lowest
3.26
2.927
2.515
2.54
2.3
History
PeriodVarhighestlowest
1 week
38.7%
2.3
2.3
1 month
62.84%
2.155
2.035
3 month
66.84%
2.064
1.471
6 month
153.17%
1.2899
1.1099
1 year
40.53%
2.3
1.07
3 year
-65.63%
9.28
1.07
5 year
-79.81%
15.8
1.07
10 year
-79.81%
15.8
1.07
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Assets 82,306,000 106,785,000 96,069,000 UNPUB
Current Assets 48,904,000 73,622,000 62,991,000 UNPUB
Current Liabilities 5,478,000 4,900,000 2,899,000 UNPUB
Equity 74,792,000 99,949,000 91,335,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 74,792,000 99,949,000 91,335,000 UNPUB
Liabilities 7,514,000 6,836,000 4,734,000 UNPUB
Liabilities And Equity 82,306,000 106,785,000 96,069,000 UNPUB
Noncurrent Assets 33,402,000 33,163,000 33,078,000 UNPUB
Noncurrent Liabilities 2,036,000 1,936,000 1,835,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -9,924,000 -5,538,000 -37,280,000 UNPUB
Net Cash Flow, Continuing -9,924,000 -5,538,000 -37,280,000 UNPUB
Net Cash Flow From Financing Activities UNPUB UNPUB 0 UNPUB
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 0 UNPUB
Net Cash Flow From Investing Activities UNPUB UNPUB -25,029,000 UNPUB
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -25,029,000 UNPUB
Net Cash Flow From Operating Activities -9,924,000 -8,221,000 -12,251,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -9,924,000 -8,221,000 -12,251,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Comprehensive Income/Loss -10,772,000 -9,579,000 -10,349,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -10,772,000 -9,579,000 -10,349,000 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Basic Earnings Per Share -1 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -10,772,000 -9,579,000 -10,349,000 UNPUB
Income/Loss From Continuing Operations Before Tax -10,772,000 -9,579,000 -10,349,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -10,772,000 -9,579,000 -10,349,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -10,772,000 -9,579,000 -10,349,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -10,772,000 -9,579,000 -10,349,000 UNPUB
Operating Expenses 11,110,000 10,354,000 11,198,000 UNPUB
Operating Income/Loss -11,110,000 -10,354,000 -11,198,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-14 2023-03-30
Assets 161,378,000 154,706,000 149,586,000 92,793,000
Current Assets 79,325,000 72,788,000 67,565,000 59,518,000
Current Liabilities 2,958,000 3,276,000 6,280,000 6,475,000
Equity 156,318,000 149,379,000 141,093,000 84,183,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 156,318,000 149,379,000 141,093,000 84,183,000
Liabilities 5,060,000 5,327,000 8,493,000 8,610,000
Liabilities And Equity 161,378,000 154,706,000 149,586,000 92,793,000
Noncurrent Assets 82,053,000 81,918,000 82,021,000 33,275,000
Noncurrent Liabilities 0 0 2,213,000 2,135,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-14 2023-03-30
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -8,156,000 -6,217,000 -4,571,000 -28,424,000
Net Cash Flow, Continuing -8,156,000 -6,217,000 -4,571,000 -28,424,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Operating Activities -8,156,000 -6,217,000 -4,571,000 -28,424,000
Net Cash Flow From Operating Activities, Continuing -8,156,000 -6,217,000 -4,571,000 -28,424,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-14 2023-03-30
Comprehensive Income/Loss -9,864,000 -9,247,000 -10,471,000 -87,966,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -9,864,000 -9,247,000 -10,471,000 -87,966,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-14 2023-03-30
Basic Earnings Per Share -1 -1 -1 -6
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -6
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -9,864,000 -9,247,000 -10,471,000 -87,966,000
Income/Loss From Continuing Operations Before Tax -9,864,000 -9,247,000 -10,471,000 -87,966,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -9,864,000 -9,247,000 -10,471,000 -87,966,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -9,864,000 -9,247,000 -10,471,000 -87,966,000
Net Income/Loss Available To Common Stockholders, Basic -9,864,000 -9,247,000 -10,471,000 -87,966,000
Operating Expenses 9,859,000 9,283,000 10,598,000 88,428,000
Operating Income/Loss -9,859,000 -9,283,000 -10,598,000 -88,428,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-12 2021-11-12 2022-03-24
Assets 191,682,000 184,305,000 177,170,000 170,548,000
Current Assets 110,241,000 102,582,000 95,558,000 88,346,000
Current Liabilities 4,206,000 2,677,000 4,046,000 4,401,000
Equity 183,871,000 178,521,000 170,748,000 163,995,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 183,871,000 178,521,000 170,748,000 163,995,000
Liabilities 7,811,000 5,784,000 6,422,000 6,553,000
Liabilities And Equity 191,682,000 184,305,000 177,170,000 170,548,000
Noncurrent Assets 81,441,000 81,723,000 81,612,000 82,202,000
Noncurrent Liabilities 0 0 2,376,000 2,152,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-12 2021-11-12 2022-03-24
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities -450,000 0 1,000 -449,000
Net Cash Flow From Financing Activities, Continuing -450,000 0 1,000 -449,000
Net Cash Flow From Investing Activities 5,616,000 7,446,000 7,092,000 29,362,000
Net Cash Flow From Investing Activities, Continuing 5,616,000 7,446,000 7,092,000 29,362,000
Net Cash Flow From Operating Activities -5,166,000 -7,446,000 -7,093,000 -28,913,000
Net Cash Flow From Operating Activities, Continuing -5,166,000 -7,446,000 -7,093,000 -28,913,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-12 2021-11-12 2022-03-24
Comprehensive Income/Loss -8,499,000 -7,384,000 -9,817,000 -34,506,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -8,499,000 -7,384,000 -9,817,000 -34,506,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-14 2021-08-12 2021-11-12 2022-03-24
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -8,499,000 -7,384,000 -9,817,000 -34,506,000
Income/Loss From Continuing Operations Before Tax -9,000,000 -7,972,000 -10,503,000 -36,860,000
Income Tax Expense/Benefit -501,000 -588,000 -686,000 -2,354,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -8,499,000 -7,384,000 -9,817,000 -34,506,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -8,499,000 -7,384,000 -9,817,000 -34,506,000
Net Income/Loss Available To Common Stockholders, Basic -8,499,000 -7,384,000 -9,817,000 -34,506,000
Operating Expenses 9,005,000 7,971,000 10,506,000 36,867,000
Operating Income/Loss -9,005,000 -7,971,000 -10,506,000 -36,867,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★
10:30
United States
★★
09:00
United States
★★
09:00
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:ELDN240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:ELDN240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:ELDN240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:ELDN240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:ELDN240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:ELDN240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:ELDN240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:ELDN240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:ELDN240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:ELDN240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:ELDN240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:ELDN240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:ELDN240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:ELDN240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:ELDN240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:ELDN240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:ELDN240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:ELDN240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:ELDN240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:ELDN240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:ELDN240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:ELDN240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:ELDN240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:ELDN240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:ELDN240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:ELDN240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:ELDN240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:ELDN240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:ELDN240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:ELDN240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:ELDN231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:ELDN231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:ELDN231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:ELDN231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:ELDN231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:ELDN231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:ELDN231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:ELDN231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:ELDN231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:ELDN231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:ELDN231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:ELDN231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:ELDN231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:ELDN231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:ELDN231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:ELDN231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:ELDN231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:ELDN231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:ELDN230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:ELDN230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:ELDN230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:ELDN230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:ELDN230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:ELDN230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:ELDN230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:ELDN230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:ELDN230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:ELDN230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:ELDN230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:ELDN230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Earnings Releases and Operating Results
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
GlobeNewswire Inc. • 1w ago
News Clinical Study
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
GlobeNewswire Inc. • 1mo ago
stocks Clinical Study
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
GlobeNewswire Inc. • 1mo ago
News Clinical Study
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
GlobeNewswire Inc. • 1mo ago
Health Health
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
GlobeNewswire Inc. • 1mo ago
Stocks Changes in company's own shares
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc. • 3mo ago
Health Health
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
GlobeNewswire Inc. • 4mo ago
Stocks Stock Market News
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc. • 5mo ago
Calendar Calendar of Events
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
GlobeNewswire Inc. • 5mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT